· 09/786108 - 5650

PATENT COOPERATION TREATY

REC'D	15	MAY	2001
WIFO		F	CT

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

11

Applicant's or agent's file reference	FOR FURTHER ACT		ication of Transmittal of International	
3875-4000PC1			y Examination Report (Form PCT/IPEA/416)	
International application No.	International filing date	(aay/montn/year)	Priority date (day/month/year)	
PCT/US99/19902 31 AUGUST 1999		1.170.0	31 AUGUST 1998	
International Patent Classification (IPC) or national classification and IPC Please See Supplemental Sheet.				
Applicant THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK				
This international prelimina Examining Authority and is	ary examination report transmitted to the appl	t has been prepa icant according to	red by this International Preliminary Article 36.	
2. This REPORT consists of a	total of sheets.		•	
This report is also accombeen amended and are th	This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).			
These annexes consist of a to	otal of sheets.			
3. This report contains indication	is relating to the follow	ing items:		
I Basis of the repor	rt			
	, -			
II Priority		_		
III X Non-establishmen	III X Non-establishment of report with regard to novelty, inventive step or industrial applicability			
IV X Lack of unity of	invention			
	V X Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement			
VI Certain documents	cited			
VII Certain defects in t	he international applicati	ion		
VIII Certain observation	VIII Certain observations on the international application			
-				
1				
Date of submission of the demand		Date of completion of this report		
30 MARCH 2000		01 APRIL 2001		
Name and mailing address of the IPEA/US		Authorized officer		
Commissioner of Patents and Trademarks Box PCT		MICHAEL PAK		
Washington, D.C. 20231 Facsimile No. (703) 305-3230		Telephone No. (703) 308-0196		
1 acadimic 140. (703) 303-3230		- Diophono 110.	(103) 300-0130	

International application No.

PCT/US99/19902

I. Ba	isis f the	report		
1 With	regard to th	e elements of the interna	ational application:*	
X	the interna	ational application as	originally filed	
	the descri		,	
X	pages			, as originally filed
	pages	NONE		, filed with the demand
	pages	NONE	, filed with the letter of	
	P-8			
\mathbf{x}	the claims	s:		os originally filed
	pages	61-68	, as amended (together with a	ony statement) under Article 19
	pages		, as amended (together with a	filed with the demand
	pages	NONE NONE	, filed with the letter of	
	pages	NONE	, filed with the foliation of	
x	the drawi	ngs:		
نک	20000	1-9		, as originally filed
	pages	NONE		, filed with the demand
	pages	NONE	, filed with the letter of	
X	the seque	nce listing part of the c	description:	as originally filed
	pages	NONE		filed with the demand
	pages	NONE	, filed with the letter of	
	pages	110112	,	
			the international application (under Rule 48.2 mished for the purposes of international preliminar	
3. W	ith regard to reliminary e	o any nucleotide and/o examination was carrie	or amino acid sequence disclosed in the internated out on the basis of the sequence listing:	tional application, the international
X	contained	d in the international	application in printed form.	•
			tional application in computer readable form.	
	_		Authority in written form.	
<u> </u>	J		Authority in computer readable form.	
				t go beyond the disclosure in the
	→ internation	onal application as filed		
	The states been furn	ment that the informationished.	on recorded in computer readable form is identical	to the writen sequence listing has
4. X	The ame	endments have resulte	ed in the cancellation of:	
4. 🗠			NONE	
		e description, pages		
	_	e claims, Nos.	NONE	
_		e drawings, sheets/fip		
5.	This repo	ort has been drawn as if	(some of) the amendments had not been made, sir	nce they have been considered to go
in	eplacement s this report	the same distribution in house for	as indicated in the Supplemental Box (Rule 70.2(c) trnished to the receiving Office in response to an invidual are not annexed to this report since they do n	itation under Article 14 are referrea to
l a	nd 70.17).		ich amendments must be referred to under item 1	

International application No. PCT/US99/19902

III.	Non	establishment of opinion with regard t novelty, inventive step and industrial applicability			
1. T	1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been and will not be examined in respect of:				
		the entire international application.			
	x	claims Nos. <u>23-31, 39, 47-52, and 54-68</u>			
	_	because: the said international application, or the said claim Nos. relate to the following subject matter which does not require international preliminary examination (specify).			
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify).			
		the claims, or said claims Nos are so inadequately supported by the description that no meaningful opinion could be formed.			
	X	no international search report has been established for said claims Nos. (See Attached)			
2.	A me seque	aningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid nee listing to comply with the standard provided for in Annex C of the Administrative Instructions: the written form has not been furnished or does not comply with the standard. the computer readable form has not been furnished or does not comply with the standard.			

International application No.
PCT/US99/19902

]	IV. Lack of unity f inventi n	
	1. In response to the invitation to restrict or pay additional fees the applicant has:	
	x restricted the claims.	
	paid additional fees.	
	paid additional fees under protest.	
	neither restricted nor paid additional fees.	
:	2. This Authority found that the requirement of unity of invention is not complied with and chose, according to not to invite the applicant to restrict or pay additional fees.	o Rule 68.1,
	3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is	
	complied with.	
	X not complied with for the following reasons:	
	Please See Supplemental Sheet.	
	·	
	·	
		ļ
	4. Consequently, the following parts of the international application were the subject of international preliminary examining establishing this report:	nation
	all parts.	
	X the parts relating to claims Nos. 1-21, 32-38, and 40-45.	

International application No. PCT/US99/19902

V.	Reasoned statement under Article 35(citati ns and explanati ns supporting	2) with r gas such stateme	rd to novelty, inventive step or industrial applica	.bility; 	
1.	statement				
	Novelty (N)	Claims	(Please See supplemental sheet)	YES	
	Hovely (11)	Claims	(Please See supplemental sheet)	NO	
		G1 :	(Please See supplemental sheet)	YES	
	Inventive Step (IS)	Claims		NO	
		Claims	(Please See supplemental sheet)		
			The second sheets	YES	
Ì	Industrial Applicability (IA)	Claims	(Please See supplemental sheet)	IES NO	
		Claims	(Please See supplemental sheet)	NO	
Claims 1-10, 12-15, 17-22, 32-36, 38, and 40-44 lack novelty under PCT Article 33(2) as being anticipated by SHI et al. SHI et al. disclose nucleic acid molecule encoding ERG1, ERG2, and ERG3(figures 1-3 and Table 1). SHI et al. disclose vector comprising the above nucleic acid molecule and host cells comprising the vectors (pages 9423-9425; figures 1-8). Claims 11, 16, 37, and 45 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest he claimed products. Claims 1-21, 32-38, and 40-45 meet the criteria set out in PCT Article 33(4), because the products can be used for diagnostics. NONE					
	Claims 1-21, 32-38, and 40-45 meet the crit diagnostics. NEW CITATIONS		PCT Article 33(4), because the products can be used for	Γ	

International application No.

PCT/US99/19902

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

CLASSIFICATION:

The International Patent Classification (IPC) and/or the National classification are as listed below: IPC(7): C07K 14/00, 14/435; C12N 5/16, 15/12, 15/63, G01N 33/53, 33/566 and US C1.: 435/6, 7.2, 320.1, 325; 530/350; 536/23.5

III. NON-ESTABLISHMENT OF REPORT:

No international search report has been established for claim numbers 23-31, 39, 47-52, and 54-68.

IV. LACK OF UNITY OF INVENTION:

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2, and 13.3 is not complied with for the following reasons:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-21, 32-38, and 40-45, drawn to an isolated nucleic acid.

Group II, claim(s) 22, drawn to an isolated polypeptide.

Group III, claim(s) 46, drawn to a method for identifying a compound.

Group IV, claim(s) 53, drawn to a method of detecting the prsence of elk1.

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The inventions listed as Groups I-IV do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features because the product of claim 1 is anticipated by SHI et al. (J. Neuroscience. 15 December 1997. Vol. 17, No. 24, pp. 9423-9426) and thus, does not share a special technical feature with any other group.

The special technical feature of Group I is a nucleic acid, vector and host cell. Pursuant to 37 CFR 1.475(d), these claims are considered by the ISA/US to constitute the main invention, and none of the related groups II-XII correspond to the main invention.

The product of Group II does not share the same or corresponding special technical feature with Group I, because they are drawn to products having materially different structures and functions, and each defines a separate invention over the art.

The methods of Groups III-IV, do not share the same or corresponding special technical feature with each other, because the methods have materially different process steps and are practiced for materially different purposes, and each defines a separate invention over the art.

Since Groups I-IV do not share a special technical feature, unity of invention is lacking.

3...

V. 1. REASONED STATEMENTS:

The report as to Novelty was positive (YES) with respect to claims 11, 16, 37, and 45.

The report as to Novelty was negative (NO) with respect to claims 1-10, 12-15, 17-21, 32-36, 38, 40-44.

The report as to Inventive Step was positive (YES) with respect to claims 11, 16, 37, and 45.

The report as to Inventive Step was negative (NO) with respect to claims 1-10, 12-15, 17-21, 32-36, 38, 40-44.

The report as to Industrial Applicability was positive (YES) with respect to claims 1-21, 32-38, 40-45.

The report as to Industrial Applicability was negative (NO) with respect to claims NONE.